Skip to main content
. Author manuscript; available in PMC: 2018 Sep 19.
Published in final edited form as: Nature. 2017 Nov 8;551(7681):512–516. doi: 10.1038/nature24462

Figure 2: Neoantigen quality is prognostic of survival.

Figure 2:

(a) Survival of patients with tumors harboring both greater than the median number of neoantigens (NeoantigenHi), and CD3-CD8 double positive cells (CD3-CD8Hi), compared to all other patients (Rest), as determined by the MSKCC and pVAC-Seq neoantigen prediction pipelines. (b) Patient survival stratified by neoantigen quality and quantity in the MSKCC and ICGC cohorts. n = biologically independent samples in individual patients. P-values were determined using log-rank test (a, b).